Kura Oncology at ASCO: Strategic Moves in AML Treatment

Kura Oncology (NASDAQ:KURA) presented positive data at ASCO 2025 for Ziftamenib, highlighting the FDA's acceptance of its New Drug Application with priority review and a PDUFA target date of November 30, 2025. The COMET-one trial demonstrated significant improvement in remission rates for AML patients, with a median overall survival of 16.4 months for responding patients and a favorable safety profile. Kura plans to initiate COMMOD 17 Phase three trials in the second half of this year, supported by over $700 million in reserves and potential near-term milestones of $375 million; however, differentiating Ziftamenib from competitors remains a key challenge.

Analysis

Kura Oncology's presentation at the ASCO 2025 meeting highlighted compelling clinical data for Ziftamenib in treating relapsed/refractory NPM1-mutant Acute Myeloid Leukemia (AML), significantly bolstered by the FDA's acceptance of its New Drug Application (NDA) with priority review and a PDUFA target date of November 30, 2025. The pivotal COMET-one trial successfully met its primary endpoint, demonstrating a complete remission/complete remission with partial hematologic recovery (CR/CRH) rate of 23% in the Phase 2 cohort, which was statistically superior (p=0.0058) to the 12% historical control rate with salvage chemotherapy. Importantly, responding patients achieved a median overall survival of 16.4 months, compared to 3.5 months for non-responders, and 65% of these responses were MRD negative. Ziftamenib exhibited a favorable safety profile, characterized by low rates of myelosuppression (20-22% for key cytopenias) and a low discontinuation rate of 3% due to adverse events. A critical differentiating factor is the absence of clinically significant QTc prolongation with Ziftamenib, contrasting with competitor menin inhibitors like Revumenib where QTc issues were dose-limiting. While differentiation syndrome was observed in 23% of patients (15% Grade 3), it proved manageable with no Grade 4/5 events or related fatalities. Kura Oncology's financial standing is robust, with over $700 million in cash reserves as of Q1-end and the potential to earn an additional $375 million in near-term milestones, supporting ongoing R&D and commercialization efforts. Future catalysts include preliminary data from the COMET-seven Phase 1b trial at the upcoming EHA meeting and the planned initiation of COMMOD 17 Phase 3 trials in the second half of 2025. Physician feedback from the event underscored Ziftamenib's once-daily dosing, superior tolerability, and lack of cardiac monitoring requirements as key advantages that could position it as a best-in-class agent, though effectively communicating these differentiators in the market will be essential.

Key Decisions for Investors

• Consider the positive COMET-one trial results and FDA priority review for Ziftamenib as significant de-risking events, with the November 30, 2025 PDUFA date being a primary near-term catalyst.
• Assess Kura's potential to capture market share in NPM1-mutant AML, focusing on Ziftamenib's differentiating factors such as its favorable safety profile, particularly the absence of QTc prolongation and lower myelosuppression, and its convenient once-daily dosing regimen compared to competitors.
• Monitor upcoming milestones, including preliminary data from the COMET-seven Phase 1b trial at EHA, the initiation and progress of the COMMOD 17 Phase 3 trials in H2 2025, and the company's execution of commercial launch preparations, as these will be critical for validating long-term value.
• Recognize that Kura's strong cash position, exceeding $700 million, supplemented by potential near-term milestones of $375 million, substantially funds current development programs and initial commercialization efforts, mitigating near-term financing risks.